Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: A median follow-up of 63.4 months

BMC Cancer

Volumn 9, Issue , 2009, Pages 375-

  Huang, Ou ^a,b   Chen, CanMing ^b   Wu, JiaYi ^a   Chen, ShuJie ^b   Chen, XiaoSong ^a   Liu, GuangYu ^b   Hu, Zhen ^b   Lu, JingSong ^b   Wu, Jiong ^b   Shao, ZhiMin ^b   Shen, ZhenZhou ^b   Shen, KunWei ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; NAVELBINE; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASPIRATION BIOPSY; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART FUNCTION; HUMAN; HUMAN TISSUE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR LOCALIZATION;

EID: 70450240804     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-375     Document Type: Article

References (41)

1. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002, 20(17):3628-3636. 10.1200/JCO.2002.02.026, 12202663.
2. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351(9114):1451-1467. 10.1016/S0140-6736(97)11423-4, 9605801.
3. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11(2):155-168.
4. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17(5):1474-1481.
5. Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. The New England journal of medicine 1978, 299(24):1330-1334.
6. Lippman ME, Allegra JC. Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 1980, 46(12 suppl):2829-2834. 10.1002/1097-0142(19801215)46:12+<2829::AID-CNCR2820461419>3.0.CO;2-M , 7448729.
7. Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. The American surgeon 1996, 62(2):162-165.
8. Conti F, Vici P. [Vinorelbin in the treatment of breast cancer: current status and prospectives for the future]. La Clinica terapeutica 1998, 149(921):61-74.
9. Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000, 18(12):2385-2394.
10. Pronzato P, Tognoni A, Pensa F, Vaira F, Vigani A. A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancer. Journal of chemotherapy (Florence, Italy) 1998, 10(4):326-330.
11. Nistico C, Garufi C, Barni S, Frontini L, Galla DA, Giannarelli D, Vaccaro A, D'Ottavio AM, Terzoli E. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol 1999, 10(8):937-942. 10.1023/A:1008324329562, 10509155.
12. Ejlertsen B, Hojris I, Hansen S, Moholt K, Kristensen B, Mouridsen HT, Andersen J, Rose C, Kjaer M. Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group. Breast (Edinburgh, Scotland) 2003, 12(1):42-50.
13. Chen CM, Shen KW, Liu GY, Wu J, Lu JS, Zhuang CJ, Han QX, Liu BL, Shao ZM, Shen ZZ. [A study of the combination of vinorelbine and epirubicin as neoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer]. Zhonghua wai ke za zhi [Chinese journal of surgery] 2006, 44(11):745-747.
14. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008, 26(5):786-790. 10.1200/JCO.2008.15.0243, 18258987.
15. Zhang BN, Zhang HM. [The status and prospect of breast-conserving surgery in China]. Zhonghua yi xue za zhi 2008, 88(2):73-76.
16. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. The Surgical clinics of North America 2003, 83(4):803-819. 10.1016/S0039-6109(03)00034-3, 12875597.
17. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16(8):2672-2685.
18. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. Journal of the National Cancer Institute 2005, 97(3):188-194.
19. Hage JA, Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001, 19(22):4224-4237.
20. Nistico C, De Matteis A, Rossi E, Carnino F, Valenza R, Agostara B, Bria E, Farris A, Cremonesi M, D'Ottavio AM. Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer. Anticancer research 2005, 25(2B):1343-1348.
21. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D. Phase II study of neoadjuvant docetaxel/vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer. Clinical breast cancer 2006, 6(6):511-517. 10.3816/CBC.2006.n.004, 16595034.
22. Abrial C, Van Praagh I, Delva R, Leduc B, Fleury J, Gamelin E, Sillet-Bach I, Penault-Llorca F, Amat S, Chollet P. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer. The oncologist 2005, 10(4):242-249. 10.1634/theoncologist.10-4-242, 15821244.
23. Nole F, Minchella I, Colleoni M, Orvieto E, Munzone E, de Braud F, Peruzzotti G, Martinelli G, Zampino MG, Catania C. Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). Ann Oncol 1999, 10(8):993-996. 10.1023/A:1008389106575, 10509165.
24. Orlando L, Colleoni M, Curigliano G, Nole F, Ferretti G, Masci G, Peruzzotti G, Minchella I, Intra M, Veronesi P. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. Anticancer research 2001, 21(6A):4135-4139.
25. Braud AC, Levy E, Feuilhade F, Otmezguine Y, Calitchi E, Kirova Y, Le Bourgeois JP. Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase II study. American journal of clinical oncology 2002, 25(3):303-307. 10.1097/00000421-200206000-00021, 12040294.
26. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006, 24(13):2019-2027. 10.1200/JCO.2005.04.1665, 16606972.
27. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003, 21(22):4165-4174. 10.1200/JCO.2003.12.005, 14559892.
28. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005, 11(24 Pt 1):8715-8721. 10.1158/1078-0432.CCR-05-0539, 16361558.
29. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004, 10(19):6622-6628. 10.1158/1078-0432.CCR-04-0380, 15475452.
30. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. British journal of cancer 2004, 91(12):2012-2017. 10.1038/sj.bjc.6602235, 2409783, 15558072.
31. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001, (30):96-102.
32. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005, 23(36):9304-9311. 10.1200/JCO.2005.02.5023, 16361629.
33. Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC, Dowsett M. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast cancer research and treatment 1999, 53(1):51-59. 10.1023/A:1006179511178, 10206072.
34. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocrine-related cancer 2003, 10(1):91-98. 10.1677/erc.0.0100091, 12653672.
35. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, Wagstaff J, Pinedo HM. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. British journal of cancer 1998, 77(4):621-626. 2149927, 9484820.
36. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, Cirillo F, Bolsi G, Bertoli G, Alquati P. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer research 1996, 16(5B):3105-3110.
37. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR, Dowsett M. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast cancer research and treatment 1998, 48(2):107-116. 10.1023/A:1005933815809, 9596482.
38. Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast cancer research and treatment 1998, 48(1):11-20. 10.1023/A:1005973529921, 9541185.
39. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. J Clin Oncol 2005, 23(11):2477-2492. 10.1200/JCO.2005.07.559, 15767642.
40. Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S, Makris A. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res 2006, 8(3):R31. 10.1186/bcr1508, 1557736, 16790076.
41. Billgren AM, Rutqvist LE, Tani E, Wilking N, Fornander T, Skoog L. Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta oncologica (Stockholm, Sweden) 1999, 38(5):597-601. 10.1080/028418699431186, 10427948.